PTGX
Protagonist Therapeutics, Inc.
Stock
$140.06+0.87 (+0.63%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $131M | $58M | $184M | −$70M | −$108M | −$108M | −$72M | −$42M | −$50M | $3.9M | −$30M | −$14M | −$7.7M |
| Capital expenditures | $615K | $1.6M | $1.4M | $609K | $795K | $1.1M | $471K | $967K | $486K | $666K | $347K | $399K | $299K |
| Free cash flow | $131M | $56M | $183M | −$71M | −$109M | −$109M | −$73M | −$42M | −$50M | $3.2M | −$30M | −$15M | −$8.0M |
| Stock-based compensation | $50M | $46M | $38M | $29M | $24M | $16M | $7.9M | $8.4M | $6.9M | $4.2M | $2.1M | $99K | $42K |
| Free cash flow margin | 46.3% | 121.9% | 42.1% | −118.1% | −409.8% | −398.3% | −254.8% | −18,395.7% | −163.1% | 16.0% | — | — | — |